Evaluation of efficacy and safety of an enhanced influenza vaccination schedule in immunocompromised children undergoing treatment for cancer.

Phase 4

Completed

• Conditions: Respiratory - Other respiratory disorders / diseases; Public Health - Other public health; Influenza infection; Response to influenza vaccine; Infection - Studies of infection and infectious agents; Cancer; Cancer - Children's - Brain; Cancer - Children's - Leukaemia & Lymphoma; Infection - Other infectious diseases; Cancer - Children's - Other

• Registration Number: ACTRN12620000548932
• Lead Sponsor: CAHS

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-05-08
• Study Completion: 2021-12-17
• Last Update Posted: 10 October 2022

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 78

Inclusion Criteria

Male or female children of grater than or equal to 6 months and lest than or equal to 18 years of age undergoing therapy for cancer or within 6 months of completion of treatment.

Children immunosuppressed as a result of cancer therapy. This includes chemotherapy and radiotherapy but excludes biological agents such as Rituximab.

Patients receiving the influenza vaccine outside the hospital will be included provided that the dose and type of vaccine corresponds to the one recommended by the Health Department.

Exclusion Criteria

Known contraindication to influenza vaccine as defined by the Australian Immunisation Handbook 10th Edition.

Patients who have received immunoglobulins within the last three months preceding the influenza vaccination.

Patients with a history of Guillain-Barre syndrome post influenza vaccine.

Patients post autologous or allogeneic haematopoietic stem cell transplantation.

Patients with non-malignant haematological disease.

Study & Design

• Study Type: Interventional
• Study Design: Not specified